Unknown

Dataset Information

0

Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.


ABSTRACT: Histone deacetylase (HDAC) inhibitors show clinical promise for the treatment of cancers, including hepatocellular carcinoma (HCC). In this study, we investigated the effect of HDAC inhibitor treatment on hepatitis C virus (HCV) replication in Huh7 human liver cells and in a mouse model of HCV infection. Viral replication was markedly suppressed by the HDAC3 inhibitor at concentrations below 1 mmol/L, with no cellular toxicity. This was accompanied by upregulation of liver-expressed antimicrobial peptide 1(LEAP-1) and downregulation of apolipoprotein-A1 (Apo-A1), as determined by microarray and quantitative RT-PCR analyses. Moreover, HDAC3 was found to modulate the binding of CCAAT-enhancer-binding protein ? (C/EBP?), hypoxia-inducible factor 1? (HIF1?), and signal transducer and activator of transcription 3 (STAT3) to the LEAP-1 promoter. HDAC3 inhibitor treatment also blocked HCV replication in a mouse model of HCV infection. These results indicate that epigenetic therapy with HDAC3 inhibitor may be a potential treatment for diseases associated with HCV infection such as HCC.

SUBMITTER: Zhou Y 

PROVIDER: S-EPMC6235766 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.

Zhou Yuan Y   Wang Qian Q   Yang Qi Q   Tang Jielin J   Xu Chonghui C   Gai Dongwei D   Chen Xinwen X   Chen Jizheng J  

Virologica Sinica 20181017 5


Histone deacetylase (HDAC) inhibitors show clinical promise for the treatment of cancers, including hepatocellular carcinoma (HCC). In this study, we investigated the effect of HDAC inhibitor treatment on hepatitis C virus (HCV) replication in Huh7 human liver cells and in a mouse model of HCV infection. Viral replication was markedly suppressed by the HDAC3 inhibitor at concentrations below 1 mmol/L, with no cellular toxicity. This was accompanied by upregulation of liver-expressed antimicrobia  ...[more]

Similar Datasets

| S-EPMC3638752 | biostudies-literature
| S-EPMC4699768 | biostudies-literature
| S-EPMC8111102 | biostudies-literature
| S-EPMC4000116 | biostudies-literature
| S-EPMC4523338 | biostudies-literature
| S-EPMC546162 | biostudies-literature
| S-EPMC2292526 | biostudies-literature
| S-EPMC6382829 | biostudies-literature
| S-EPMC5642598 | biostudies-literature
| S-EPMC7176913 | biostudies-literature